Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody

Bone health is an important consideration in patients with solid tumours, as both metastasis to bone and cancer therapy-induced bone loss (CTIBL) can increase morbidity and reduce quality of life [1,2]. Bone is a common site of metastasis in patients with cancer, with prostate, breast and lung the most frequent tumours leading to bone metastasis, accounting for 34%, 22% and 20% of cases, respectively [3]. A recent study in patients with solid tumours in the USA estimated the incidence of bone metastases in patients with solid tumours to be 6.9% at 5 years after diagnosis and 8.4% at 10 years [4], while a meta-analysis of 156 studies in breast cancer found that a median of 12% of patients with stage I –III breast cancer developed bone metastases during a median follow-up period of 60 months [5].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: General and Supportive Care Source Type: research